Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 11%

Rapport Therapeutics (NASDAQ:RAPP)’s stock price rose 11% on Tuesday . The company traded as high as $22.87 and last traded at $22.72. Approximately 51,085 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 215,976 shares. The stock had previously closed at $20.47.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RAPP. Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price for the company. Stifel Nicolaus began coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, TD Cowen assumed coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating on the stock.

Rapport Therapeutics Stock Up 9.8 %

Insider Activity at Rapport Therapeutics

In other news, Director James Healy acquired 44,032 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was acquired at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the transaction, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.